Influenza vaccines can be produced faster using a new insect cell-based technology compared with traditional egg-based processes, according to scientists in Vienna, Austria.
Influenza vaccines can be produced faster using a new insect cell-based technology than traditional egg-based processes, according to scientists in Vienna, Austria. The new technique involves using insect cells to create recombinant influenza virus-like particles (VLPs) that resemble virus particles, but lack the viral nucleic acid, which means they are not infectious.
"Recent outbreaks of influenza highlight the importance of a rapid and sufficient vaccine supply for pandemic and inter-pandemic strains," said Florian Krammer, co-author of the University of Natural Resources and Applied Life Science study in Vienna, in a press statement.
Traditional influenza vaccines are produced in embryonated chicken eggs and although they can be manufactured in sufficient quantities for seasonal influenza strains, the method may be insufficient in a pandemic situation because of limited egg supply.
Using the new insect cell-based method, the Austrian team took only 10 weeks to produce swine-origin pandemic H1N1 swine-flu influenza VLPs for immunological studies in mice. Conventional production methods, however, would take months. Using insect cells also overcomes some of the problems associated with egg-based methods, such as allergic reactions to egg proteins and biosafety issues.
"Our work demonstrates that recombinant influenza VLPs are a very fast, safe and efficient alternative to conventional influenza vaccines and represents a significant new approach for newly emerging influenza strains such as H1N1 or H5N1," said Krammer in the release.
The study appears in the Biotechnology Journal.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.